Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Increases By 12.6%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a significant growth in short interest during the month of October. As of October 15th, there was short interest totalling 121,900 shares, a growth of 12.6% from the September 30th total of 108,300 shares. Based on an average daily volume of 279,800 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.4% of the shares of the stock are sold short.

Coeptis Therapeutics Price Performance

NASDAQ:COEP remained flat at $0.21 during trading hours on Wednesday. The company’s stock had a trading volume of 82,703 shares, compared to its average volume of 320,516. The company has a market capitalization of $7.75 million, a PE ratio of -0.39 and a beta of -0.91. Coeptis Therapeutics has a 1-year low of $0.15 and a 1-year high of $1.33. The company’s 50 day moving average price is $0.19 and its 200 day moving average price is $0.26.

Coeptis Therapeutics (NASDAQ:COEP) last announced its quarterly earnings results on Friday, August 16th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. Sell-side analysts anticipate that Coeptis Therapeutics will post -0.26 EPS for the current fiscal year.

Coeptis Therapeutics Company Profile

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.